An accumulating body of experimental dam supports the presence of a paracrine pathway for the modulation of myocardial function by cardiac endothelial cells. Cardioactive substances released by endothelial cells include nitric oxide, endothelin-1, prostanoids, adenylpurines, natriumtic peptides, and other agents that have so far only been characterised in bioassay studies. Endothelial cells also possess enzymatic activities, in particular ACE/kininase activity, which can alter local levels of angiotensin II and bradykinin. Many of the "endothelial" mediators can be produced by cardiac myocytes themselves, often under pathological conditions, suggesting a potential parallel autocrine pathway. Complex reciprocal relationships exist between individual mediators, which affect both their release and actions. Most studies to date have focused on the acute influence of these agents on contractile function; the longer-term modulation both of cardiac structure and function could be equally important. A notable feature of the action of several of the endothelial mediators is that they modify myocardial contractile behaviour predominantly through changes in myofilament properties rather than by altering cytosolic CaZC transients. This mode of action often results in a disproportionate effect on myocardial relaxation and diastolic tone. The opposing contractile effects and differing time-scales of action of agents such as nitric oxide and endothelin-1 are reminiscent of the interplay between these factors in the regulation of blood vessel tone. The endothelial paracrine pathway is likely to act in concert and to interact with other cardiovascular regulatory pathways, e.g., the Frank-Starling mechanism, neurohumoral influences, the effects of heart rate, coronary perfusion and load. A better understanding of its physiological and pathophysiological roles may lead to novel therapeutic strategies.
Introduction
The paracrine influence of endothelial cells on various functions of the peripheral vasculatnre (e.g., the regulation of vascular tone and repair, and the inhibition of platelet adhesion and aggregation) is well recognised. The initial suggestion that endothelial cells influence myocardial contractile function came from Brutsaert and co-workers who reported that selective denudation of endocardial endothelium in isolated cat cardiac papillary muscles resulted in characteristic changes in contractile behaviour of these preparations: an abbreviation of the duration of contraction and a slight reduction in peak force without major reduction in the rate of force development [l-3] . Similar effects could be demonstrated after procedures that attempted to selectively impair endocardial endothelial function in the whole heart, both in dogs in vivo [4] and in the isolated ferret heart [5] , although the relative magnitude of change was much smaller. It was also shown that endocardial endothelial cells modified the inotropic response of mammalian (cat, rat, rabbit) papillary muscle preparations to various receptor-mediated agonists [6-91, implying a perhaps more subtle modulatory influence. Subsequent studies utilising isolated ferret and rat papillary muscle preparations and cultured porcine ventricular endocardial endothelial cells demonstrated definitively that these influences on myocardial contractile function involved the release of diffusible factors by endocardial endothelial cells [ 10,111, i.e., a paracrine action. However, the physiological relevance of these data has always been controversial given Time for primary review 37 days.
at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from that the endocardial endothelial monolayer lining the inner cavitary surfaces of the heart is in close contact with only a tiny proportion of the total myocardial mass, at least in the adult. On the other hand, at the level of the coronary microvasculature, there is intimate contact between endothelial cells and cardiac myocytes throughout the heart, with no cardiac myocyte being more than 2-3 pm from a coronary vascular endothelial cell. In view of this spatial proximity, a physiologically relevant paracrine interaction between these cell types is more plausible. Indeed, an accumulating body of experimental data supports the presence of a paracrine pathway for the modulation of myocardial function by cardiac endothelial cells. Evidence for such a pathway in humans in vivo has also been reported recently [12, 13] .
Despite the doubts regarding the relevance of endocardial endothelial influences in the adult heart in vivo, the study of endocardial endothelial function in the isolated cardiac papillary muscle has remained a useful experimental approach to exploring endothelial-myocyte interactions; endocardial cells comprise the majority of noncapillary endothelial cells in this preparation. There is broad similarity between endocardial and vascular endothelial cells, but it should be noted that there are also significant differences, for example with respect to embryological origin, cytoskeletal organisation [ 141, growth rates in culture [ 151, electroph ysiological properties [ 16,171, certain receptor-mediated functions [16] , and the release of prostanoids [151. The endocardial endothelium may have various specialised functions, e.g., in cardiac morphogenesis. A role in regulating paracellular transport has been suggested [18] . It has also been speculated that factors released by endocardial endothelial cells might influence cardiac neuronal function in view of the close proximity (within 1 pm> of an extensive subendocardial neural plexus comprising heterogeneous nerve fibres [19] . However, in isolated ferret papillary muscles selective denudation of the endocardial endothelium had no discernible effect on action potential characteristics [20] . A detailed review of endocardial endothelial cell structure and function has been published [14] .
Cardioactive factors released by endothelial cells include nitric oxide (which acts primarily through elevation of myocardial cGMP), endothelin-1 , prostanoids, adenylpurines, and a number of other substances that have been character&d in bioassay studies but are as yet chemically unidentified. In addition, cardiac endothelial cells possess enzymatic activities, e.g., angiotensin converting enzyme (ACE) and kininase activity, which contribute to changes in local levels of substances such as angiotensin II and bradykinin. Of note is the fact that many of these endothelial factors modify myocardial contractile behaviour through changes in cardiac myofilament properties rather than by altering cytosolic Ca2' transients [21] ; this mechanism distinguishes them from most other endogenous inotropic factors (e.g., catecholamines) involved in cardiac regulation, which exert marked effects on intracellular Ca2+ cycling processes as well as myofilament propertres in some cases [22] . The present review focuses on the influences of these endothelial factors on myocardial function and their possible physiological and pathophysiological relevance.
Nitric oxide
Nitric oxide has pivotal inter-and intra-cellular signalling roles in many physiological processes, e.g., endothelial regulation of vascular tone, inhibition of platelet adhesion and aggregation, neurotransmission, and macrophage cytotoxicity (reviewed in [23] ). Its molecular biology and biochemistry have been reviewed in detail [23, 24] . Three isoforms of nitric oxide synthase (NOS) have so far been identified: NOS-1 (or nNOS), originally found in neuronal tissue; NOS-2 (or inducible NOS, iNOS), originally identified in macrophages; and NOS-3 (or endothelial NOS, eNOS), originally found in endothelial cells. All three isoforms have subsequently been demonstrated in other tissues.
As a consequence of its potent vasodilator activity, endothelium-derived nitric oxide clearly has the potential to indirectly influence cardiac function secondary to alterations in (i> arterial tone and cardiac load, (ii) venous return and capacitance, and thus ventricular filling volume, thereby modulating stroke output via the Frank-Starling mechanism, and (iii) coronary vascular tone and coronary perfusion. In addition to these indirect effects, nitric oxide has direct actions on cardiac myocytes. The precise effects on myocardial function are likely to depend on the cellular source of production of nitric oxide, the amount released (isofonn dependent), and on underlying physiological and pathophysiological conditions. Potential cellular sources of nitric oxide within the heart include endoaelial cells (particularly coronary microvascular endothelium) [23] , cardiac myocytes themselves [25] , nerve tissue [26] and white blood cells [27] . Physiological and pathophysiological factors that may influence the release or actions of nitric oxide include the coronary flow rate and heart rate (both of which may alter fluid shear stress), the level of p-adrenergic and cholinergic activation, the type of cardiac myocyte (atrial, ventricular or conducting tissue), interaction with other paracrine factors, and the presence of immune activation or inflammation (which may induce expression of NOS-2).
Basal systolic and diastolic function
There is now convincing evidence from studies in several different species to support a role for endothelium-derived nitric oxide in modulating basal myocardial function, particularly relaxation and diastolic tone. In isolated ferret papillary muscles, the stimulation of nitric oxide release Representative example of the effect of endocardium-derived nitric oxide on basal isometric twitch contraction of an isolated ferret papillary muscle, following stimulation by substance P (sub P, 1 PM). C = control trace. Reproduced from [224] with permission of Elsevier Science Iteland Ltd.
from endocardial endothelium using the agonist substance P induced an earlier onset of isometric twitch relaxation and a slight reduction in peak force, but no change in the early phase of contraction, e.g., in the maximal rate of force development [lo] - Fig. 1 . These effects were associated with elevation of papillary muscle cGMP content and were abolished either by denudation of endocardial endothelium or by haemoglobin, which inactivates nitric oxide. Similar effects were observed in this preparation with the exogenous nitric oxide donor, sodium nitroprusside, or with a lipid-soluble cGMP analogue, 8-bromo-cGMP [ 10,281. This pattern of myocardial response, with a disproportionate effect on late systole and relaxation, differs from the actions of most conventional therapeutic agents, e.g., Ca2+ antagonists, fl-adrenergic block-'00-l b) ers, phosphodiesterase inhibitors, which generally alter both early systolic function and relaxation. In the isolated ejecting ("working") guinea-pig heart, studied under conditions of constant filling pressure, a&load and heart rate, both an exogenous nitric oxide donor (sodium nitroprusside) and agents that release nitric oxide from coronary vascular endothelial cells (e.g., substance P or bradykinin) induced a dose-dependent earlier onset and acceleration of left ventricular (LV) pressure fall (measured using an intracavitary high-fidelity pressure transducer) [29, 30] . These LV relaxant effects were not accompanied by a significant change in peak LV dP/dt,,, a pattern similar to that observed in isolated papillary muscles - Fig. 2 . All three agents increased coronary flow but there was no correlation between the magnitude of increase in coronary flow and the enhancement of LV relaxation; furthermore, a cGMP-independent coronary vasodilator (the Ca*+-antagonist nicardipine) which increased coronary flow to the same extent as the nitric oxide-dependent agents failed to produce similar LV relaxant effects [29] . Neither substance P nor bradykinin had any direct myocardial effects in isolated guinea-pig papillary muscles [30] . These data, together with the findings that haemoglobin inhibited the changes in LV relaxation (Fig. 2) , support the hypothesis that nitric oxide exerts direct actions on cardiac myocyte contraction. Thus, endothelium-derived nitric oxide selectively modulates LV relaxation in the isolated whole heart without major effect on early systolic pressure develop- In isolated single rat ventricular myocytes studied in the absence of agonist stimulation, the cGMP analogue 8-bromo-cGMP (used as a surrogate for nitric oxide) induced a similar pattern of effects to those described above, i.e., an earlier onset of isotonic twitch relaxation and a reduction in amplitude of twitch shortening without significant reduction in shortening velocity [31] . These changes were unaccompanied by any alteration in the cytosolic Ca*' transient or in the action potential, suggesting that they were mediated by a cGMP-induced reduction in myofila-'+ ment response to Ca (Fig. 3) . Such a subcellular mechanism was also supported by studies of the steady-state relationship between cell shortening and cytosolic Ca*' in intact myocytes tetanized by high frequency stimulation following inhibition of the sarcoplasmic reticulum ATPase by thapsigargin; 8-bromo-cGMP decreased steady-state tetanic shortening without reducing peak steady-state tetanic Ca*+ (Fig. 4) [31]. 8-bromo-cGMP appeared to act by stimulating cGMP-dependent protein kinase (PKG) since its effects were inhibited by KT5823, a specific inhibitor of the kinase [31] . A previous study in skinned porcine cardiac fibres also reported a PKG-induced reduction in the Ca*' sensitivity of force production [32] , and a recent preliminary report confirms similar findings in human cardiac fibres [33] . In addition to the changes in twitch amplitude and relaxation in rat myocytes, B-bromocGMP also induced a significant increase in myocyte diastolic length without any change in diastolic cytosolic Ca*+. This acute increase in diastolic length, which was also observed in quiescent (i.e., electrically unstimulated) cardiac myocytes, may reflect a reduction in intrinsic diastolic tone in these externally mechanically-unloaded cells, perhaps secondary to the reduction in myofilament response to Ca*+; consistent with previous reports [34] , it implies that active cross-bridge cycling during diastole may contribute to "diastolic tone".
Recent studies have explored the presence of similar effects of nitric oxide in human subjects [12, 13] Representative example of effect of low-dose bicoronary sodium nitroprusside infusion (SNP I.C., 4 pg/min) on high-fidelity left ventricular pressure (LVP, left) and on diastolic pressure-volume relations (right) in a normal human subject undergoing diagnostic cardiac catheterization. SNP induced earlier LV relaxation, reduced peak systolic pressure and end-diastolic pressure but had no effect on LV dP/dr,,, . The diastolic pressure-volume relation was shifted down, consistent with increased LV distensibility. Reproduced from 12241 with permission of Elsevier Science Ireland Ltd.
nitroprusside simultaneously into both coronary arteries, dividing the total dose in accordance with angiographic coronary anatomy in order to achieve a homogenous delivery of the drug throughout the myocardium. A 5 min bicoronary infusion of sodium nitroprusside induced a significant reduction in peak LV systolic pressure and an earlier onset of LV relaxation (i.e., a reduced time to LV dP/dr,,), but no change in LV dP/dr,,, (Fig. 5) . LV end-diastolic pressure was reduced with an accompanying increase in LV end-diastolic volume, and there was a downward shift in the end-diastolic LV pressure-volume relation, consistent with an increase in LV end-diastolic distensibility. These changes were not accompanied by any reduction in LV ejection fraction or in stroke volume, despite the fall in peak LV systolic pressure (Fig. 6) . Infusion of an identical dose of sodium nitroprusside into the right atrium failed to reproduce these effects, indicating that they were unlikely to be due to spillover of the drug into the systemic circulation. In view of the similar pattern of change in LV relaxation and diastolic function in patients to that observed in the experimental in vitro studies discussed previously, these effects are consistent with a cGMP-mediated action on human myocardium. In further studies using a similar investigation protocol, the effects of bicoronary infusion of substance P, which releases nitric oxide from coronary vascular endothelium, have been examined both in subjects with atypical chest pain but normal coronaries and normal LV function, and in cardiac transplant recipients free of rejection or graft vasculopathy being catheterised at annual follow-up [13] . In both groups of patients, bicoronary substance P infusion induced similar effects to those of sodium nitroprusside, with a fall in peak LV systolic pressure, an earlier onset of LV relaxation, no significant change in LV d P/dt,,,,, , and an increase in LV end-diastolic volume without significant change in LV end-diastolic pressure -consistent with an increase in LV end-diastolic distensibility. The similar pattern of effect of intracoronary substance P in cardiac transplant recipients, who have deficient cardiac imrervation, to that observed in normal subjects makes it unlikely that cardiac autonomic reflexes contributed to the changes in LV function. Right atrial infusion of substance P again failed to reproduce these effects, making a systemic action unlikely. These studies provide the first clinical evidence for a paracrine effect of factors (probably nitric oxide) released from coronary vascular endothelium on LV contractile function.
Interaction with the @adrenergic and cholinergic pathways
Two broad types of studies have been performed to investigate the possible role of nitric oxide in modulating these pathways, those that have studied intra-myocyte production of nitric oxide and those that have looked at exogenous nitric oxide. In adult rat ventricular myocytes, Balligand and colleagues reported that intra-myocyte production of nitric oxide by a NOS-3 isoform reduced the inotropic response to P-adrenergic stimulation [35, 36] . The positive inotropic response to isoproterenol was augmented by the nitric oxide synthase (NOS) inhibitor N"-nitro-Larginine, although the inhibitor had no effect on basal contraction; this was accompanied by a decrease in nitric oxide production assessed by a reporter cell assay. NOS-1 was not expressed in rat cardiac myocytes in contrast to rat skeletal muscle where NOS-1 has been identified [37] . In anaesthetised dogs, vagal inhibition of the inotropic re-LV dP/dl,.. at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from sponse to dobutamine was found to be attenuated by the NOS inhibitor NG-monomethyl-L-arginine (L-Nh4MA) [38] , suggesting that at least part of this parasympathetic inhibition was mediated by nitric oxide. However, the cell type that produced nitric oxide could not be determined in this in vivo study. L-Nh4MA did not alter the inotropic response to aadrenergic stimulation itself in this study [38] , in contrast to the findings in isolated adult rat myocytes [35] . In spontaneously beating neonatal cultured rat cardiac myocytes, Balligand and colleagues found that NOS inhibitors blocked the negative chronotropic action of the muscarinic agonist carbachol, suggesting that nitric oxide mediated this response [35] . Whether carbachol responses in adult rat myocytes were mediated via nitric oxide was not investigated. In spontaneously beating adult rabbit sino-atria1 cells, Han and co-workers reported that cholinergic inhibition of isoproterenol-stimulated Ca2' current was mediated via intra-myocyte generation of nitric oxide [39] , suggesting a potential influence on heart rate although no measurements of beating rate were reported. (A reduction in spontaneous beating frequency was also reported in neonatal rat myocytes following induction of NOS-2 by interleukin-lP or lipopolysaccharide, which could be inhibited by NOS inhibitors or by transforming growth factor p, TGFP > [40, 41] . In addition to the work of Balligand et al. [35, 36] , biochemical evidence for constitutive Ca'+-dependent production of nitric oxide by adult rat cardiac myocytes was also reported by Schulz and colleagues [25] . However, a study in isolated adult guinea-pig ventricular myocytes failed to detect any evidence of constitutive NOS activity and demonstrated that the cGMP-elevating effects of carbachol in this species were not mediated by nitric oxide [42] . Constitutive NOS could also not be detected by immunocytochemistry using a NOS-3-specific monoclonal antibody in rabbit cardiac myocytes in situ [27] .
Both in adult guinea-pig myocytes [43] and in frog myocytes [44] , an exogenous nitric oxide donor, SIN-l, has been shown to modulate padrenergic responses. In the guinea-pig, SIN-l inhibited CAMP-stimulated sarcolemmal L-type Ca" current via a PKG-mediated mechanism [43] whereas in the frog a similar inhibition involved activation of a CAMP-phosphodiesterase presumably leading to reduction in CAMP levels [44] .
A number of studies also suggest the potential for a positive inotropic action of exogenous nitric oxide, mediated via modulation of the P-adrenergic pathway. In both the studies involving SIN-l referred to above [43, 44] , low concentrations of the drug inconsistently increased CAMP-stimulated CaZf current, possibly via inhibition of a CAMP-phosphodiesterase and a consequent increase in CAMP levels -compatible with a positive inotropic response. In a recent study in isolated human atrial myocytes [45] , low doses of SIN-l (> 1 PM) produced a profound increase in basal Ca2' current, apparently via a cGMP-inhibited phosphodiesterase. In a study of the effect of 8-bnomo-cGMP in isolated adult rat cardiac myocytes, a transient positive inotropic response associated with an increase in amplitude of the cytosolic Ca2' transient was observed in about 50% of cells [31] . In cat papillary muscle preparations, it was reported that low concentrations of sodium nitroprusside had a positive inotropic effect whereas higher concentrations induced negative inotropic changes [46] . A preliminary study in adult rat myocytes also noted a biphasic inotropic response to exogenous nitric oxide-donor drugs, with an increase in twitch amplitude at low concentrations of the drugs and a decrease in twitch amplitude at higher concentrations [47] . In contrast, no positive inotropic effect was observed in guinea-pig cardiac myocytes exposed to nitric oxide-donor drugs or to authentic nitric oxide in solution [48] .
Subcellular mechanisms
Most of the cardiac actions of constitutively-derived nitric oxide appear to be mediated through stimulation of soluble guanylyl cyclase and elevation of intracellular cGMP. The subcellular mechanisms of action of cGMP have been reviewed in detail elsewhere [24, 49] . The major target proteins for cGMP in myocardium are cGMP-dependent protein kinases (PKG) and cGMP-regulated cyclic nucleotide phosphodiesterases. The former potentially alter function via phosphorylation, while the latter modulate intracellular levels of CAMP (either increasing or decreasing them depending on the phosphodiesterase). The relative importance of these pathways in different parts of the heart, different species, and under different conditions of myocardial activation has not been worked out in detail. The complexity of possible responses is further increased by the multiple isoforms of cGMP target proteins, cross-reaction between CAMP-and cGMP-activated kinases, subcellular compartmentation of cGMP and/or its target proteins, and the presence of cGMP-activated phosphatases. Actions that have been attributed to cGMP in heart include (i) modulation of sarcolemmal Ca2+ influx (either an increase or a reduction), generally only in the presence of elevated CAMP, (ii) reduction in Ca2+-sensitivity of myofilament force production, (iii) changes in action potential characteristics, (iv) phosphorylation of sarcoplasmic reticular proteins, (v) modulation of cell volume [50] , and (vi) reduction in myocardial oxygen consumption [51] . The effects of nitric oxide/cGMP on myocardial relaxation and diastolic tone discussed above appear to result from a PKG-mediated reduction in myofilament response to Ca2+ [31, 32] . On the other hand, the modulation of P-adrenergic responses is likely to involve changes in sarcolemmal Ca2+ influx mediated via PKG and/or via cGMP-regulated phosphodiesterases [43, 44] .
In many tissues, nitric oxide has cGMP-independent activity via reactions with transition metals and thiol groups in numerous targets, including membrane receptors and ion channels, cytosolic and mitochondrial enzymes, signalling molecules, gene transcription factors and nucleic acids [52] . There is some evidence also for cGMP-independent actions of nitric oxide in the heart. Nitric oxide synthase inhibitors are reported to increase oxygen consumption independent of cGMP and independent of their haemodynamic effects, suggesting that nitric oxide reduces oxygen consumption possibly via actions on mitochondrial aconitase [53] . In keeping with this, an earlier study showed that nitric oxide potently and reversibly deenergized mitochondria, particularly under hypoxic conditions [54] . The large amounts of nitric oxide produced by NOS-2 (in contrast to NOS-1 and NOS-3) may react directly with mitochondrial respiratory enzymes and with various nuclear proteins, to cause cellular damage by these mechanisms. Indeed, this appears to the major mode of action of the cytotoxic effect of nitric oxide on tumour cells and parasites. In addition, the reaction of nitric oxide with oxygen free radicals such as superoxide CO;), e.g., during ischaemia-reperfusion, can form peroxynitrite (OONO-) which is a potent oxidant and highly toxic [52, 55, 56 ].
Physiological and pathophysiological roles of NOS-3-derived nitric oxide
The most relevant physiological stimuli for the release of nitric oxide from coronary vascular endothelial cells in vivo may be flow-induced shear stress and the cyclical mechanical deformation of the endothelium that occurs during the cardiac cycle [571. In view of the characteristic alterations in onset of LV relaxation and in LV end-diastolic distensibility induced by endothelium-derived nitric oxide, the following physiological regulatory role is suggested. During physiological increases in heart rate and/or coronary flow (as during exercise) when the higher frequency and velocity of pulsatile coronary flow augments nitric oxide release [57, 58] , enhanced LV relaxation and improved diastolic distensibility may benefit both subendocardial coronary perfusion and ventricular filling by increasing the diastolic interval, increasing the driving pressure for cardiac filling, and reducing extravascular compressive forces. This nitric oxide-dependent pathway could therefore facilitate the acute matching of the pattern of ventricular contractile function to changes in coronary flow and/or heart rate, perhaps even on a beat-to-beat basis.
A physiological influence of myocyte-derived nitric oxide in the absence of agonist stimulation remains to be demonstrated; the physiological stimuli that might activate myocyte NOS-3 are unclear. However, either myocyte-derived and/or endothelium-derived nitric oxide could potentially modulate padrenergic responses, both with respect to inotropic and chronotropic state as discussed above. Whether such a mechanism is relevant across a broad range of mammalian species, and particularly in humans, and under what circumstances there is inhibition or potentiation of padrenergic responses remains to be established. In preliminary studies in human subjects, the magnitude of reduction in peak LV systolic pressure caused by endothelium-derived nitric oxide (using intracoronary substance P infusion) was markedly increased in the presence of /3-adrenergic stimulation (W.J. Paulus and A.M. Shah, unpublished observations). Possibly, the presence of an activated /3-adrenergic pathway (e.g., as in heart failure) predisposes to a greater negative inotropic effect of nitric oxide.
Studies to date have investigated only the acute influences of the nitric oxide pathway on myocardial function. An important question yet to be addressed is whether chronic changes in nitric oxide pathways, either physiological or pathophysiological, may influence cardiac structure and function. For example, is it possible that the increases in coronary endothelial nitric oxide production known to occur with chronic exercise [59] contribute to cardiac dilatation in trained athletes, as a result of alteration in LV distensibility? Vascular endothelial dysfunction and abnormal production of nitric oxide are well recognised in conditions such as ischaemia-reperfusion, hypertension, LV hypertrophy, heart failure, and hypercholesterolaemia. Could increases in nitric oxide production in heart failure [60] contribute to cardiac remodelling? Could reductions in nitric oxide contribute to the abnormal LV relaxation and the reduced LV distensibility observed in LV hypertrophy [61] or in the cardiac allograft [62] , thereby compromising cardiac filling and subendocardial coronary perfusion (i.e., causing "diastolic dysfunction")? The possible influence of nitric oxide on myocardial growth, hypertrophy and fibrosis is unknown. It has been reported that chronic nitrate therapy attenuates long-term changes in ventricular structure following experimental myocardial infarction in dogs, an action that is not accounted for by changes in cardiac loading [63] .
Conversely, agents that exert selective effects on myocardial relaxation and diastole via nitric oxide/cGMP-de-F ,,I
,I -8bCGyP c n RI R5 R10 c n ill RI R10 Fig. 7 . Effect of 8-bromo-cGMP (8bcGMP, 50 PM) on parameters of twitch relaxation in single rat cardiac myocytes subjected to 10 min hypoxia followed by reoxygenation. C = baseline control; H = 9 min hypoxia; RI, R5, and RlO = 1, 5 and 10 min reoxygenation respectively. l P < 0.05 for comparison between groups by ANOVA. In untreated myocytes, reoxygenation was accompanied by a marked increase in the time to peak shortening and the half-relaxation time. In the presence of 8bcGMP. these relaxation abnormalities were fully inhibited. Reproduced from [64] with permission of the American Physiological Society.
at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from pendent mechanisms might prove useful as part of the therapeutic approach to "diastolic heart failure". In an experimental model of acute "diastolic dysfunction", involving brief hypoxia-reoxygenation in isolated single rat cardiac myocytes, pretreatment with the cGMP analogue 8-bromo-cGMP completely inhibited the abnormalities of relaxation and diastolic tone [64] (Fig. 7) ; the mechanism appeared to involve an alteration in the myotilament response to Ca" since the contractile changes were not accompanied by corresponding changes in Ca2+ transient. In a model of myocardial stunning following brief (10 min) coronary occlusion in conscious dogs, Hasebe and colleagues [65] reported that inhibition of NOS enhanced myocardial depression independent of changes in coronary flow, implying that nitric oxide had a protective effect against myocardial stunning. The effects on relaxation and diastolic function were not reported. However, Ehring and colleagues [66] reported that inhibition of NOS did not affect stunning after 15 min coronary occlusion in anaesthetised dogs. The disparities between these studies could possibly relate to the different preparations studied (i.e., conscious versus anaesthetised). Nitric oxide also protected isolated rat cardiac myocytes against reoxygenation injury following prolonged anoxia [67] . Although the mechanism was not elucidated, nitric oxide-induced reduction in myofilament response to Ca" could contribute to this protective effect by reducing cellular hypercontracture caused by Ca2+ overload during reoxygenation. Enhancement of the nitric oxide pathway improved cardiac preservation in a heterotopic rat transplant model, possibly by improved vascular function (blood flow, decreased leucocyte adhesion) as well as beneficial myocardial effects [68] . Nitric oxide also contributed to the antiarrhythmic effects of ischaemic preconditioning in canine myocardium [69] .
On the other hand, nitric oxide could theoretically be deleterious in the context of ischaemia-reperfusion, e.g., through reaction with superoxide to form toxic peroxynitrite radicals [55] . In a rabbit model of regional myocardial ischaemia, infarct size was reduced by pretreatment with a NOS inhibitor, suggesting an adverse effect of nitric oxide [70] . Similarly, a NOS inhibitor improved myocardial functional recovery following ischaemia-reperfusion in isolated rat hearts, despite lower baseline contractile performance and coronary flow [7 13.
NOS-2 (iNOS) in myocardial disease
Following the recognition of the effects of constitutive NOS (NOS-3) on myocardial function, attention has turned also to the role of NOS-2. Cardiac diseases where an immune or inflammatory mechanism may be implicated include endotoxic shock, cardiac allograft rejection, myocarditis and myocardial infarction. Biochemical evidence for Ca2+-independent production of nitric oxide in cardiac tissue was first reported by Schulz and colleagues who studied rat cardiac myocytes isolated from animals treated with endotoxin [25] . Subsequently, a variety of cytokines as well as medium conditioned by activated macrophages were shown to induce expression of NOS-2 activity in myocardial tissue in several different species, both in vitro and ex vivo [72-761. The production of nitric oxide was also demonstrated by electron paramagnetic resonance studies in rejecting cardiac grafts in an experimental rat model of transplantation [77] . NOS-2 mRNA and protein were demonstrated in rejecting rat cardiac allografts [78] , in cultured neonatal rat myocytes treated with interleukinl/3 [79] , in adult rat ventricular myocytes exposed to interleukin-1 p or interferon-y [80] , in human cardiac myocytes treated with interleukin-l/3 [81], and in cardiac tissue obtained from rats treated with lipopolysaccharide [80] . It should be noted that in addition to cardiac myocytes, several other cell types within the heart, e.g., microvascular endothelial cells [82] , endocardial endothelial cells [83] , vascular smooth muscle [23] , and inflammatory cells [27] , may contribute to NOS-2 activity. In experimental myocardial infarction, for example, NOS-2 activity appears to be attributable predominantly to infiltrating macrophages [27] . A recent study has confiied the potential for Ca2+-independent NOS activity in human endomyocardial biopsy tissue obtained from patients with dilated cardiomyopathy [84] , although the cell type responsible w,as not determined. A detailed discussion of the regulation of NOS-2 is outside the scope of this article and has been reviewed elsewhere [81] . In general, the major mechanism is thought to be regulation at the level of gene transcription, but post-translational mechanisms affecting mRNA and protein stability, substrate and co-factor synthesis, and product inhibition are also important. In addition, cytokines such as tumour necrosis factor (Y that induce NOS-2 can also reduce NOS-3 activity by decreasing mRNA stability.
Most studies that have directly investigated the functional consequences of activation of NOS-2 in myocardium have been performed in vitro. In isolated ferret papillary muscles exposed to interleukin-1P [73] , chick myocytes exposed to interleukin 6 [75] , and rat cardiac myocytes exposed to macrophage-conditioned medium [74], basal and/or p-adrenergic stimulated myocardial inotropic responses were depressed. These abnormalities were reversed by inhibitors of NOS (L-a&nine analogues) and in some cases could be prevented by pretreatment with dexamethasone. In isolated ejecting rat hearts, treatment with interleukin-lp and tumour necrosis factor (r for 2 h resulted in a depression of cardiac output which could be prevented by a NOS inhibitor or by cycloheximide (which inhibits protein synthesis) [76] . Cardiac myocytes isolated from endotoxin-treated guinea pigs had depressed basal contraction which could be improved by NOS inhibitors or by pretreatment of animals with dexamethasone [72] . However, in another study of endotoxin-treated guinea pigs, reduced contractile function of isolated hearts was not attributable to induction of NOS-2 [85] . A rapid (within minutes) nitric oxide-mediated depression of myocardial contraction following in vitro exposure to certain cytokines has also been reported 175,861. This is too rapid to be accounted for by expression of NOS-2 but probably results from cytokine-induced activation of NOS-3.
Despite these in vitro data, the consequences for cardiac function of NOS-2 activation in vivo remain to be defined. In non-cardiac tissues, activation of NOS-2 can result in beneficial or detrimental effects depending on the amount, duration and site of production/action of the nitric oxide [81] . Nitric oxide has anti-microbial and anti-viral activity [87] as well as other potentially beneficial actions on the heart (e.g., coronary vasodilatation, anti-platelet activity, decreased leucocyte adhesion, cytoprotection, enhancement of LV relaxation) [12, 23, 29, 30] . On the other hand, excessive production of nitric oxide may cause myocardial depression through several mechanisms, e.g., by cGMPmediated effects, actions on mitochondrial enzymes and nuclear proteins, and the formation of peroxynitrite [24, 52, 55, 81] . In view of these multiple actions, the effects on contractile function of nitric oxide derived from NOS-2 could well be quite different from those characteristically associated with NOS3-derived nitric oxide. Whether activation of NOS-2 is beneficial or deleterious may depend on the context: for example, it is difficult to envisage a beneficial effect of NOS-2 in cardiac allograft rejection, whereas in myocarditis activation of NOS-2 could be a vital defense mechanism. Indeed, NOS-2 knockout transgenie mice are reported to be highly susceptible to viral myocarditis [88] . The possible benefit of NOS inhibitors in cardiac conditions where activation of NOS-2 occurs thus remains to be proven.
ACE, angiotensin II and bradykinin
A locally active renin-angiotensin system is now known to be present within the mammalian heart and is involved in disease states such as LV hypertrophy and congestive heart failure [89, 90] . Angiotensin II is formed from angiotensin I by the activity of two major enzymes, ACE and heart chymase, both present widely in mammalian species including humans [91-941. ACE present on coronary microvascular endothelial cells [95, 96] , endocardial endotheha1 cells [97] , and other cardiac cell types [98] also has kininase activity, thus potentially modulating local levels of bradykinin as well as angiotensin I and II [90] . Endotheha1 cells themselves can release bradykinin probably from H-kininogen via a local kallikrein-kinin system [99] . Deletion polymorphism in the ACE gene (which correlates with ACE activity) is suggested to be an independent risk factor in myocardial infarction and other cardiac diseases [KlO] . Chronic treatment with ACE inhibitors reduces mortality and has beneficial effects on ventricular remodelling and diastolic dysfunction in heart failure and following acute myocardial infarction [lOl-1041. From a mechanistic point of view, an interesting question is the role of cardiac endothelial cells and other cardiac cells with ACE activity in these effects. It is uncertain what the relative roles of changes in systemic and local intra-cardiac ACE activity are, or the relative contribution of reduction in angiotensin II levels, increases in endogenous bradykinin levels, and enhanced interaction between bradykinin and its endothelial receptors [90, 96] .
Sarcolemmal receptors for angiotensin II are present on cardiac myocytes [105] . Angiotensin II is a direct positive inotrope in many but not all species and also facilitates sympathetic nervous influences on the heart [89] . It is reported to delay myocardial relaxation particularly in diseased hearts [89, 106, 107] . In hearts isolated from rats with LV hypertrophy, angiotensin II markedly increased LV end-diastolic pressure; this was accompanied by an increase in expression of ACE mRNA [91] . In isolated human myocardium, Holubarsch and colleagues reported that angiotensin II had no effect on contraction of either failing or non-failing ventricular tissue, but exerted modest positive inotropic effects in atrial tissue [log] . In contrast, Moravec and co-workers found a positive inotropic effect in human ventricular myocardium, although responses were heterogeneous and less marked than in atria1 tissue [109] . In most studies, the subcellular mechanism of the positive inotropic effect of angiotensin II has been suggested to be an increase in cytosolic Ca2+ (e.g., [l lo]), but a recent study in rabbit myocardium reported an increase in the myofilament response to Ca" . m this preparation, possibly secondary to an intracellular alkalosis caused by stimulation of Naf-H+ exchange [l 11,112] . In rabbit sinoatrial node cells, angiotensin II had a negative chronotropic effect by inhibiting L-type Ca" current through a CAMPdependent pathway [ 1131. Despite the evidence from these studies of exogenous angiotensin II, the contribution of endogenous angiotensin II to the physiological regulation of cardiac contractile function remains uncertain.
Bradykinin can induce the release of several endothelial autacoids, including nitric oxide, prostaglandins, ATP and endothelium-derived hyperpolarizing factor, via stimulation of B,-kinin receptors [90, 114, 115] . In isolated ejecting guinea-pig hearts, exogenous bradykinin enhances LV relaxation through the release of nitric oxide [30] , as discussed earlier. We have recently demonstrated in this preparation that similar acute changes in LV relaxation are produced by the ACE inhibitor captopril, via a mechanism that involves endogenous bradykinin [116] . The LV relaxant effect of captopril was inhibited either by a B,-kinin receptor antagonist, HOE140, or by haemoglobin, confirming the involvement of the bradykinin-nitric oxide pathway in this response. Whether similar effects occur in the human heart and whether there are chronic changes in contractile function through this mechanism is of interest. In two recent clinical studies in patients with left ventricular hypertrophy, acute left coronary infusion of the ACE inhibitor enalaprilat improved isovolumic relaxation in those with severe hypertrophy in one study [117] , and improved LV diastolic chamber distensibility and regional relaxation in the other [118] . The nature of change in LV relaxation and diastolic function in these studies is consistent with the myocardial effects of an increase in activity of the bradykinin-nitric oxide pathway, although a role of reduced angiotensin II levels is not excluded. In an earlier study of the effects of bicoronary enalaprilat infusion in patients with dilated cardiomyopathy, a reduction in stroke volume and ejection fraction was noted in the absence of evidence for peripheral haemodynamic effects, suggesting a negative inotropic effect [119] . Sarcolemmal B,-kinin receptors for bradykinin have recently been identified also in rat cardiac myocytes, but convincing evidence for a direct effect of bradykinin on myocardium is lacking [ 1201. The possible role of other endothelial factors released by bradykinin in modifying cardiac contractile performance is uncertain. In experimental studies, endogenous bradykinin has also been shown to contribute to the anti-hypertrophic [ 12 11, anti-remodelling [ 1221, cardioprotective [90] , and anti-arrhythmic effects [90] of ACE inhibitors. A recent study in anaesthetised dogs reported that pretreatment with the ACE inhibitor ramiprilat attenuated myocardial stunning following brief coronary occlusion, via a mechanism that involved bradykinin and prostaglandins but not nitric oxide [66] . Whether cardiac endothelial cells release natriuretic peptides is not known. However, in a recent study of ANP secretion by rat atrial tissue only 33% of the ANP-secreting cells were cardiac myocytes [ 13 11 . In addition to possible production of natriuretic peptides by endotbelial cells, the release of these peptides from cardiac myocytes may be influenced by endothelial signals. Secretion of ANP and BNP by cultured neonatal rat atria1 myocytes is stimulated by exogenous endothelin [ 132, 133] , and ANP release is also augmented by endogenous endothelin released by endothelial cells (bovine aortic) in co-culture [134, 135] .
On the other hand, natriuretic peptides may also influence the release of endothelial autacoids. The ANPR-A receptor, which binds both ANP and BNP, is expressed on endothelial cells [136] . ANP inhibits the release of endothelin by cultured endothelial cells 11371. The ANPR-B receptor, which binds CNP with much greater affinity than either ANP or BNP, is reported to be found in aortic but not coronary vascular smooth muscle [136] . Definitive evidence for the presence of this receptor on endothelial cells has not been reported. However, CNP inhibits both thrombin and angiotensin II-stimulated release of endothelin from cultured porcine aortic endothelial cells, more potently than either ANP or BNP [138] , suggesting that the ANPR-B receptor is indeed present in these cells. The ANPR-C or "clearance" receptor binds all three peptides (ANP :> CNP > BNP) and is present in atria1 and ventricular endocardium and mesothelial epicardium, but apparently not in coronary endothelium [ 136, 139] . Both the ANPR-A and -B receptors are coupled to guanylyl cyclases and thus cGMP production, whereas the C receptor is believed to clear natriuretic peptides from the circulation although there are data to suggest that it may also mediate physiological responses 11361. Natriuretic peptide receptors may also be coupled to inhibition of adenylyl cyclase [136] .
An influence of the natriuretic peptides on myocardial contractile function has been demonstrated in several in vitro studies. In isolated cat [140] and ferret [lo] papillary muscles, ANP induced an earlier onset of isometric twitch relaxation. Such an effect if present in vivo could facilitate more effective cardiac filling, for example during volume overload when atria1 stretch induces release of ANP. In fetal chick ventricular myocytes [141] and in neonatal rat myocytes [ 1421 ANP reduced the amplitude of contraction. A similar effect was noted in adult rat myocytes although ANP also increased the positive inotropic effect of angiotensin in this study [106] . The subcellular mechanisms of these effects may involve a rise in cGMP and/or a reduction in CAMP levels. In ferret papillary muscle [lo], fetal chick myocytes [ 1431 and rabbit ventricular myocytes 11441 the actions of ANP are related to an increase in cGMP levels. However, in neonatal rat atrial and ventricular cardiac myocytes ANP inhibits adenylyl cyclase [145] , and this has been linked to a reduction in sarcolemmal Ca2+ influx [ 1421. A cGMP-mediated reduction in sarcolemmal Ca2' current following exposure to ANP was found in rabbit ventricular myocytes [1461 and human atria1 cells [ 143, 147] , and in frog myocytes prestimulated with CAMP [148] . In human atria1 cells, ANP also increased I,, via a cGMP-independent activation of G, [ 1471. ANP decreased cell volume in rabbit myocytes by inhibiting Na+-K+-2Cl-cotransport; this was suggested to act as a negative feedback to stretch-induced release of ANF [50] . Whether the natriuretic peptides have other cGMPat Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from mediated actions similar to those of nitric oxide discussed earlier is not known.
Endothelin-1
The endotbelin family of 21 -amino acid peptides [ 1491 is distributed widely in several tissues and has a multiplicity of biological actions (see [150] [154] and by ischaemic porcine cardiac myocytes in vivo [155] has been reported recently, suggesting a potential autocrine mechanism. Epicardial mesothelial cells may also secrete endothelin-1 [ 1561. The release of endotbelin-1 from endothelial cells is sensitive to flow-induced shear stress, hypoxia and various pharmacological receptor-dependent agonists [150] . There are complex interactions between endothelin-1 and other endotbelial autacoids such as nitric oxide, angiotensin II and ANP. 
I. Inotropic and chronotropic actions of ena'othelin
Specific sarcolemmal receptors for endothelin are present on cardiac myocytes isolated from mammalian [159, 160] and human hearts [161] . Both ET, and ET, receptors have been identified on cardiac myocytes [160, 162] , and are coupled to multiple subcellular signalling pathways including stimulation of phosphoinositide hydrolysis, activation of arachidonic acid metabolism, and G protein-mediated inhibition of adenylyl cyclase [163] . The potent positive inotropic activity of exogenous endothelin-1 was demonstrated in atrial [164, 165] and ventricular [166] myocardium soon after its discovery, and has subsequently been confirmed by many laboratories [ 1501. It is effective at subnanomolar concentrations, with typically slow-onset and prolonged activity (Fig. 8) . Considerable inter-species and -tissue variation is reported with respect to the magnitude and nature of positive inotropic effect, e.g., the effect on myocardial relaxation. Endotbelin delayed myocardial relaxation under "basal" conditions in ferret [167] and rabbit [1,68] papillary muscles, but caused no change in time-courseof relaxation in another study in ferret papillary muscles [166] , or in guinea-pig atria 11641, rat cardiac myocytes [ 1521, and human atrial and ventricu- lar trabeculae [169] . The above variations may be related in part to differences in subcellular mechanisms of action, underlying myocardial contractile state, and interaction between endothelin-1 and other endogenous cardioactive factors (see below). Both an elevation of cytosolic Ca" transients [152,170] and an increase in myofilament responsiveness to Ca2' [ 167,17 11 , probably via stimulation of phosphoinositide hydrolysis [163, 168] , have been implicated in the positive inotropic activity. The raised cytosolic Ca" may result from an increase in sarcolemmal Ca2+ influx through L-type [172] and/or T-type Ca2' channels [173] and from release of Ca2' from intracellular stores [167, 170] , while the increase in myofilament responsiveness to Ca2+ is mediated, at least in part, via a protein kinase C-induced activation of Naf-H+ exchange and consequent cytosolic alkalinization [174] . In theory, endothelin-l-induced inhibition of adenylyl cyclase [163] could also contribute to an increase in Ca2' sensitivity of force production, secondary to a reduction in CAMP levels. The relative contribution of raised cytosolic Ca" and increased myofilament responsiveness to Ca2+ to the positive inotropic activity may vary according to the underlying state of myotilament activation. In isolated rabbit [168] or ferret [175] papillary muscle, no additional effect of endothelin-1 was observed in the presence of maximally effective doses of the (Y,-adrenergic agonist, phenylephrine, which increases myofilament response to Ca2'. In contrast, during acidosis in ferret papillary muscle, which reduces the myofihunent response to Ca2+, the sensitivity to endothelin-I was markedly increased with a leftward shift in the dose-response curve and a 30-fold lower minimally effective concentration of endotbelin-1 [176] . In isolated rat cardiac myocytes, nanomolar concentrations of endothelin-1 raised cytosolic Ca* + and increased contraction amplitude with little effect on twitch relaxation [152] ; however, in the presence of a novel " myofilament desensitizing agent" which reduces myofihnnent response to Ca*' (see below), similar doses of endothelin-1 increased the myofilament response to Ca*+ and significantly delayed myocardial relaxation [1771.
Endothelin-1 was reported to have negative chronotropic effects in spontaneously beating rat atria1 cells via activation of an inwardly rectifying K+ current [178] . In guineapig atria1 cells stimulated by Padrenergic agonists, endothelin-1 caused membrane hyperpolarization, a shortening of action potential duration, and a potent negative chronotropic effect, secondary both to activation of a G-protein-dependent K+ current and to reduced CAMP formation with inhibition of L-type Ca*' current [160, 179] . These effects were inhibited by an ET, receptor antagonist, BQ123, i.e., were mediated via activation of ET, receptors [160] . In the same species, an ET, selective agonist, sarafotoxin S6c, or doses of endothelin-1 lower than 10 nM increased the rate of spontaneous beating in the absence of p-adrenergic stimulation [160] , raising the possibility of bidirectional regulation of heart rate depending on the receptor subtype stimulated. In ventricular myocytes, endothelin-1 prevented /3-adrenoceptor-induced shortening of action potential duration, by inhibiting protein kinase A-dependent chloride current [ 1801. These actions have been suggested to be anti-adrenergic protective mechanisms, e.g., during myocardial ischaemia, potentially decreasing the likelihood of arrhythmia both by reducing atrial membrane excitability and by limiting the shortening of ventricular action potential duration.
Role of endogenous endothelin in heart
Despite the profusion of data regarding the myocardial activity of exogenous endothelin-1, it has been uncertain whether endogenous endothelin-1 has a physiological role in regulating cardiac function. Plasma levels of endothelin-1 are in the femtomolar range and it seems unlikely that it acts as a circulating hormone. A paracrine mode of action could result in effective local concentrations, particularly since the release of endothelin-1 from vascular endothelial cells occurs in a polar mmer preferentially towards the abluminal surface [ 1811. Concentrations of endothelin-1 that exert myocardial effects generally produce marked coronary vasoconstriction, thus potentially inducing ischaemia and counteracting positive inotropic activity. However, the relative degrees of direct myocardial inotropic activity and coronary vasoconstrictive activity may depend on the site of production of the endogenous peptide, i.e., whether at the level of the cardiac myocyte or the endocardial endothelium or coronary capillary endothelium or the resistance vasculature.
Recent studies provide evidence in support of a physiolimo tminl Fig. 9 . Effect of exposure of isolated ferret papillary muscle preparations to the endothelin receptor antagonist BQ123 (10 PM). PT = peak isometric tension, dT/dr = rate of tension development, PT = time to peak tension, RTl/2 = time to 50% tension decline, + EE = endocardial endothelium-intact preparations, -EE = endocardial endotbeliumdenuded preparations. * P < 0.05 for comparison between groups by ANOVA. BQ123 induced earlier and faster twitch relaxation in the EE-intact muscles but had little effect on the EE-denuded preparations. Reproduced from [183] with permission of the BMJ Publishing Group.
logical role for endogenous endothelin-1. Tonic release of endothelin-1 from cultured ventricular endocardial endothelial cells occurred in sufficient concentrations to induce positive inotropic effects in isolated cardiac myocytes [ 1521. In isolated rat hearts, sufficient endothelin-1 was released into the coronary circulation potentially to exert myocardial inotropic activity [182] . In isolated ferret papillary muscles exposed to the ET, receptor antagonist, BQ123, a progressively earlier onset and time-course of isometric twitch relaxation without reduction in peak isometric force was observed; in muscles denuded of endocardial endothelium, BQ123 had no significant effect [ 1831 - Fig. 9 . These data suggest a tonic release of endothelin-1 from endocardial endothelial cells in situ, with a consequent delay in myocardial relaxation. The effects of BQ123 in isolated papillary muscles are reminiscent of the effects of selective endocardial endothelial damage in this preparation first reported by Brutsaert and co-workers [l] , and suggest that at least part of the latter response is attributable to the loss of endothelin-1. In keeping with this hypothesis, it was previously shown that selective endocardial denudation in aequorin-loaded ferret papillary muscles reduced the myofilament response to Ca*', compatible with a loss of endothelin-1 activity [ 1841. Exposure of isolated rat trabeculae to BQ123 also caused reduction in peak isometric force, consistent with a reversal of basal tonic endothelin-1 activity [ 1851. In buffer-perfused isolated guinea-pig hearts, administration of BQ123 induced progressively earlier and faster LV relaxation without altering peak LV pressure, suggesting an endogenous release of endothelin-1 within the intact heart in this preparation [186] . In normal anaesthetised dogs, intravenous bolus injection of a mixed ET, and ET, receptor antagonist, bosentan, reportedly had no significant effect on LV d P/d? or cardiac output, but changes in LV relaxation were not assessed [187] . Whether endogenous endothelin-1 contributes to the physiological regulation of heart rate or other myocardial functions is at present unknown.
Pathophysiological role of endothelin
Increasing evidence supports the involvement of endothelin-1 in cardiac pathophysiological states. Production of endothelin in the heart is increased in acute myocardial ischaemia and myocardial infarction [ 1881. During regional myocardial ischaemia in pigs, endothelin-1 was produced by ischaemic cardiac myocytes in vivo [155] . Exposure to oxygen free radicals induced release of endothelin from endocardial endothelium in isolated papillary muscles [ 1891. The binding of endothelin-1 to cardiac receptors was increased following prolonged (> 30 min) ischaemia and during reoxygenation [1901. An increase in endothelin-1 could either be beneficial by improving contractile performance or deleterious by causing coronary vasoconstriction [ 1911, increasing myocardial oxygen demand and reperfttsion injury [192] , and impairing myocardial relaxation [192, 193] . Administration of BQ123 or of anti-endothelin monoclonal antibodies reduced myocardial infarct size in several experimental studies [188, 194] . In isolated rat hearts, BQ123 delayed the rise in LVEDP during global no-flow ischaemia apparently independent of changes in coronary flow [ 1951. Exogenous endothelin-1 promotes the development of experimental cardiac hypertrophy in neonatal rat cardiac myocytes via mechanisms that involve protein kinase C and mitogen-activated protein (MAP) kinases [196, 197] . A role for endogenous endothelin-1 in the development of hypertrophy is supported by studies showing that BQ123 partially blocked angiotensin II-induced hypertrophy in cultured rat cardiac myocytes 11581 and inhibited the development of pressure overload-induced LV hypertrophy in rats in vivo [ 1981. Prostanoids may have indirect effects on myocardial contraction, particularly under pathophysiological conditions, as a consequence of their vasodilator, platelet anti-aggregatory, and ill-defined "cytoprotective" action [199] . They are reported to reduce myocardial infarct size [199, 201] and to reduce the contractile deficit during recovery from ischaemia (i.e., myocardial stunning) [66, 202] . However, the direct effects of prostanoids on myocardial function remain rather uncertain (for review see [203] ). Membrane receptors for prostaglandins are certainly present on cardiac myocytes, being coupled both to adenylyl cyclase and to the phosphoinositide pathway [203] . Nevertheless, their inotropic effects are inconsistent. For example, PGI, had a positive inotropic effect in guinea-pig atria [204] , a negative inotropic effect in rat cardiac myocytes [205] , and no effect in cat papillary muscle [206] . It has been suggested that prostanoids modulate inotropic responses to other agonists [ 1071.
Adenylpurines
Both endothelial cells and cardiac myocytes release adenylpurines such as ATP and adenosine, particularly during hypoxia or ischaemia [207] . ATP may be released into the coronary circulation by endothelial cells in response to specific agonist-receptor interaction, e.g., by bradykinin [ 1151. Other sources of ATP release include platelet degranulation and sympathetic nerves, where it is coreleased with norepinephrine [208] . Adenosine may be formed intracellularly or may be generated extracellularly from ATP and ADP by membrane ecto-5'-nucleotidases. Although adenosine has potent effects on coronary blood flow via A, purinoceptors, its effects and subcellular mechanisms in myocardium are controversial, In ventricular myocardium, it is thought to exert A, purinoceptormediated negative inotropic effects, probably via inhibition of adenylyl cyclase and a reduction in CAMP levels [207] . It is suggested that it may .therefore serve as a mediator that limits the effects of catecholamines on the heart, e.g., during hypoxia or ischaemia. In cultured fetal chick ventricular cells, following inactivation of the inhibitory adenosine A, receptor pathway, stimulation of adenosine A, receptors caused an increase in intracellular CAMP and in contractile amplitude [209] . In atria1 myocardium, adenosine may exert CAMP-independent negative inotropic effects probably by activating ATP-dependent potassium channels [207] . Adenosine also inhibits the firing rate of the sinoatrial node and conduction through the atrioventricular node, probably via both CAMP-independent and -dependent mechanisms involving A, receptors. Recent studies have suggested that adenosine plays a role in the protective phenomenon of myocardial ischaemic precondi-tioning, probably via a protein kinase C-dependent mechanism [210] .
ATP can induce the release of nitric oxide from endothelial cells, and could therefore contribute to modulation of cardiac contractile function through this pathway. In isolated ejecting guinea-pig hearts, part of the LV relaxant effect of exogenous bradykinin was attributable to release of ATP [211] . A direct positive inotropic action of ATP has also been reported, mediated via PZ purinoceptors and a rise in cytosolic Ca*' [212, 213] . In adult ventricular myocytes, ATP induced phosphoinositide hydrolysis and an increase in contractile amplitude [214] . The physiological role, if any, of endogenous ATP in the regulation of myocardial contraction remains to be established.
Other substances that modify myofilament properties
There is increasing experimental evidence that endothelial cells also release other, as yet chemically unidentified, substances that influence myocardial contraction by altering contractile protein properties. These data are derived mainly from bioassay studies in which the superfusing buffer of cultured endothelial cells grown on microcarrier beads or the coronary effluent of isolated buffer-perfused hearts has been tested for its effect on contraction of various isolated myocardial preparations.
"Myofilament desensitizing agent"
In initial bioassay studies, we reported that the superfusing effluent of cultured endocardial endothelial cells induced a positive inotropic effect accompanied by twitch prolongation (termed "endocardin" activity) in isolated ferret papillary muscle preparations [lo] . Since the papillary muscle is a multicellular preparation containing numerous endothelial cells as well as cardiac myocytes, the relative contributions of these cell types to the observed responses was difficult to ascertain. In order to better define the respective roles of endothelium and myocardium, in subsequent bioassay studies we have used the isolated cardiac myocyte as the assay tissue. These studies demonstrate that cultured endocardial endothelial and vascular endothelial cells tonically release both endothelin-1 and a potent negative inotropic substance, termed "myofilament desensitizing agent" [152, 215] . The combined activity of these two factors appears to account for the "endocardin" effect previously described in isolated papillary muscles [10,1771.
Addition of endothelial cell superfusate with "myofilament desensitizing agent" activity to isolated rat cardiac myocytes resulted in a rapid and reversible reduction in contractile amplitude, an earlier onset of twitch relaxation, and an increase in diastolic cell length [215] (Fig. 10) . These effects were not accompanied by significant changes in the cytosolic Ca*+ transient or in diastolic Ca*' , indicating that they resulted from a reduction in the relative myofilament response to Ca". A similar inference was made from studies in intact single cardiac myocytes that were tetanically stimulated, where the effluent reduced tetanic shortening without altering the tetanic elevation of Ca*+. ' The pattern of change in contractile behaviour is very similar to the effects of nitric oxide/8-bromo-cGMP described earlier. However, "myofilament desensitizing agent" activity was not blocked by inhibition of the following: nitric oxide synthesis, nitric oxide action (by haemoglobin), cyclooxygenase, adenosine receptors, cGMP-dependent protein kinase, CAMP-dependent protein kinase, protein kinase C, and pertussis toxin-sensitive Gproteins [215] . Furthermore, the activity was found to be quite stable, being retained at 37°C for several hours or at 4°C for > 48 h. Preliminary characterisation indicates that the activity is attributable to a low molecular weight (< 1 kD) non-protein facto&).
In earlier studies, Winegrad and co-workers reported that the coronary effluent of isolated perfused rat hearts induced bi-directional changes in the contractile performance of isolated rat cardiac trabeculae (either increasing or decreasing peak isometric force), which were dependent on the presence of intact endothelial cells [11, 216] . In cryostatic sections of isolated cardiac preparations, gradients of actin-activated actomyosin ATPase activity were found, with high activity around blood vessels and low activity immediately below the endocardial endothelium in superfused trabeculae [217] . These dam were interpreted on the basis of release of two different cardioactive factors [11, 216, 217] , an upregulating factor later shown to be endothelin [ 1821 and an unidentified downregulating factor; it was suggested that both factors modulated actomyosin ATPase activity. We have studied the effect of the coronary effluent of buffer-perfused rat hearts on single cardiac myocytes. Effluents that induced negative inotropic activity in myocytes produced effects that were identical in character to those of the "myofilament desensitizing agent" activity discussed above; i.e., they reduced contractile amplitude without reducing cytosolic Ca*' transients [218] . It therefore appears that the "downregulating" activity reported by Ramaciotti and colleagues 12161 may be the same as the "myofilament desensitizing agent" activity that we have reported [215, 218] . The stimuli responsible for regulating the release of this factor and its possible physiological role have yet to be clearly defined. In the isolated heart studies, it was suggested that release was regulated by coronary flow rate [216] . An interaction with the CAMP pathway, possibly at the level of the contractile proteins, has also been suggested by Winegrad and colleagues [2191.
Factors released during hypoxia
In recent studies, we have found evidence for the release of a second low molecular weight factor by cultured endothelial cells that are superfused with moderately hypoxic (PO, 50 Torr) buffer for up to 5-6 h [220] . In bioassay studies using single rat cardiac myocytes, this factor was clearly distinguishable from the "myofilament desensitizing agent" activity described above. The factor released during hypoxia induced a very potent but reversible inhibition of myocyte contraction which was accompanied by markedly delayed relaxation and a significant reduction in diastolic cell length (analogous to diastolic contracture). Inhibition of contraction occurred without significant change in the cytosolic Ca*+ transient, indicating an action at the myofilament level. In studies using an in vitro motility assay with isolated cardiac actin filaments and myosin Sl, in the absence of regulatory proteins or of Ca*+ , a direct inhibition of crossbridge cycling by this factor was confirmed [220] . The factor also markedly suppressed in vitro actomyosin ATPase activity [220] . These preliminary dam raise the possibility that depression of actomyosin ATPase activity and contraction by this endothelial cell factor could reduce myocardial 0, demand and thereby serve as an adaptive mechanism to match regional myocardial 0, supply and demand. The factor could be important in cardiac pathophysiological conditions involving hypoxia or ischaemia, e.g., in myocardial hibernation where reduction in coronary flow is associated with a reversible depression of myocardial contractile function [221] .
Summary and implications for cardiovascular regulation
The experimental data reviewed in this article strongly support the existence of a paracrine pathway for the regulation of cardiac function by endothelial cells. Interestingly, many of the agents released by endothelial cells can also be produced by cardiac myocytes under certain circumstances, indicating a potential parallel autocrine pathway. Most of the studies to date have focused on acute influences on myocardial contractile behaviour, but it seems likely that longer-term modulation both of cardiac structure and function will prove to be equally important. Indeed, some evidence for heterotypic interactions between cardiac endothelial cells and cardiac myocytes with respect to growth and differentiation already exists [151, 222] .
Some of the reciprocal interactions among the various cardioactive factors released by endothelial cells have been discussed but further studies are necessary to work these out in detail. Substances such as nitric oxide, bradykinin and the "myofilament desensitizing agent" have rapidonset and rapidly reversible activity, at least with respect to contractile modulation, and may therefore be important in "short-term" regulation, perhaps even on a beat-to-beat basis. In contrast, endothelin and angiotensin II are likely to have longer-term actions. A notable feature of the contractile activity of many of these substances is their predominant influence on the myofilament proteins rather than on processes that determine cytosolic Ca*' cycling. An important consequence of this mode of action is a disproportionate effect on myocardial relaxation and diastolic tone in many cases. Nitric oxide and the "myofilament desensitizing agent" tend to enhance relaxation and reduce diastolic tone whereas endothelin and angiotensin II may have opposing effects. Since modulation of the myofilament response to Ca*+ is also the major subcellular mechanism underlying the length-tension relationship in heart muscle [223] , interaction between some of the endothelial factors and the Frank-Starling mechanism is probable. The endothelial pathway is also likely to act in concert and to interact with other cardiovascular regulatory pathways, e.g., neurohumoral influences, the effects of heart rate, cardiac loading, and coronary perfusion (Fig.  11) . In contrast to the neurohumoral pathways, which generally have widespread actions on myocardium, the endothelial system appears primarily to be a local paracrine Endothehum-derived factors may exert indirect effects on the heart secondary to changes in preload and afterload and modulation of core nary flow, and direct effects via actions on cardiac myocytes and on heart rate. There are potential interactions among all of these pathways and also with various neurohumoral influences (e.g., @-adrenergic stimulation). Reproduced from [21] with permission of Monduzzi Editore.
pathway, perhaps reflecting an older system in evolutionary terms. Important signals for regulation of the endothelial system include flow-induced shear, mechanical forces, changes in ambient PO,, and many receptor-dependent agonists The data discussed above suggest that fundamental adaptive processes that may be mediated, at least in part, by endothelial cell factors include (i) the matching of pattern of ventricular function to changes in heart rate and coronary flow, and (ii) the matching of myocardial oxygen supply and demand.
Under pathophysiological conditions, there may be alterations both in the release of endothelial factors and in the responses of diseased myocardium to these factors. Irma-myocyte production of some of the prototypic endothelial mediators (e.g., nitric oxide, endothelin) is implicated in some pathophysiological states. The role of endothelial factors in the development of ventricular hypertrophy and remodelling processes, and in disease states character&d by systemic endothelial dysfunction or by cardiac diastolic dysfunction merits particular attention. A better understanding of the role of the cardiac endothelial pathway in the physiological regulation of heart structure and function and in the pathophysiology of disease states may lead to novel therapeutic strategies.
